ScinoPharm Taiwan, Ltd. (TPE:1789)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
17.90
-0.30 (-1.65%)
Sep 9, 2025, 1:35 PM CST
-1.65%
Market Cap14.15B
Revenue (ttm)3.19B
Net Income (ttm)204.67M
Shares Out790.74M
EPS (ttm)0.26
PE Ratio69.16
Forward PE49.72
Dividend0.35 (1.92%)
Ex-Dividend DateJul 3, 2025
Volume414,764
Average Volume563,686
Open18.20
Previous Close18.20
Day's Range17.85 - 18.20
52-Week Range16.25 - 25.80
Beta0.32
RSI61.19
Earnings DateNov 5, 2025

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, India, the United States and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; outsourcing services. It offers CRAM services, such as chemistry skill, analytical... [Read more]

Sector Healthcare
Founded 1997
Employees 540
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 1789
Full Company Profile

Financial Performance

In 2024, ScinoPharm Taiwan's revenue was 3.41 billion, an increase of 6.91% compared to the previous year's 3.19 billion. Earnings were 339.35 million, an increase of 18.22%.

Financial Statements

News

There is no news available yet.